Pancreatic differentiation from pluripotent stem cells： Tweaking the system  

作　　者：Andrew M Holland Andrew G Elefanty Edouard G Stanley 

机构地区：[1]Monash Immunology and Stem Cell Laboratories, Level 3, Building 75, Monash University, Clayton, 3800,

出　　处：《Cell Research》2009年第4期395-396,共2页细胞研究（英文版）

摘　　要：Autoimmune destruction of insulin producing pancreatic β cells results in type 1 diabetes, a condition for which there is presently no cure. Clinical trials indicate that, in some instances, control of blood glucose can be restored by transplantation of cadaveric derived islets [1], raising hopes that such cell- based therapies may eventually form part of a curative treatment. However, even if the outcome of islet transplan- tation can be significantly improved, the availability of this treatment option will always be limited by the dearth of cadaveric islet donors. It is in this context that the derivation of β cells from human embryonic stem cells （hESCs） represents an important step toward the creation of an inexhaustible source of therapeutic replacement cells for the treatment of type 1 diabetes.

关 键 词：人类胚胎干细胞 胰腺癌 调整系统 多能性 细胞治疗 分化 胰岛移植 自身免疫性 

分 类 号：Q813[生物学—生物工程] TQ522.15[化学工程—煤化学工程]